tamoxifen
Astrazeneca
['ovarian']
#asco22 #mlmasco - dfs improves by 5.2% at 96 month follow-up when 2-yr ovarian ablation added to tamoxifen in women who remained or restored premenopausal status after adj ct in ebc (korean astrra trial). no os difference. 
"What we cannot speak about we must pass over in silence" (L. Wittgenstein)